ACTRN12620001227987已完成1 期
A single dose, randomized, blinded, bioavailability study of a test formulation of iron(3+);(2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal;trihydroxide tablet in a 2 way crossover comparison against the innovator iron(3+);(2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal;trihydroxide tablet conducted under fasting conditions with diet control in healthy male volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- Male
入选标准
- •Healthy males
- •Aged between 18 and 55
- •Non-smoker
- •BMI between 18.5 and 32.0 inclusive
- •Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
- •Able to provide written informed consent
排除标准
- •Any history of recent recurrent attacks of bronchitis, asthma, migraine headaches
- •Concomitant drug therapy of any kind
- •Sensitivity to iron(3+);(2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal;trihydroxide or any other similar class of medicines, or any excipients in either formulation.
- •History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
- •Smoker (anyone who has smoked in the last 6 months)
- •History of alcohol or drug abuse or dependency
- •Participation in a drug study within 30 days of the start of the study or donated blood in the 30 days preceding the study.
- •Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk
研究者
相似试验
已完成
1 期
Comparative assessment of the absorption of an Iron Polymaltose tablet against an innovator product conducted in iron deficient participants under fed conditions with diet control (low iron and low fat).Iron DificiencyDiet and Nutrition - Other diet and nutrition disordersBlood - AnaemiaACTRN12623001001684Zenith Technology Corporation Limited24
已完成
1 期
Comparative assessment of the absorption of a generic formulation of Iron Polymaltose tablet against the innovator Maltofer tablet conducted in iron deficient participants under fed conditions with diet control.Iron DificiencyBlood - AnaemiaDiet and Nutrition - Other diet and nutrition disordersACTRN12623000530628Zenith Technology Corporation Limited12
已完成
1 期
Comparative assessment of the absorption of a generic formulation of tiotropium test product 1 and tiotropium test product 2 against the innovator Spiriva HandiHaler conducted under fasting conditions in healthy male and female volunteersACTRN12615000073505Zenith Technology Corp Ltd24
已完成
1 期
Comparative assessment of the absorption of a test formulation of 1 x 30 mg alitretinoin capsule against the innovator 1 x 30 mg alitretinoin capsule conducted under fed conditions in healthy male volunteers.Bioequivalence study conducted in healthy volunteers comparing a formulation of alitretinoin with no health condition or problem studied. Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, alitretinoin is a medicine that is used to treat severe chronic eczema that is unresponsive to treatment with potent topical corticosteroids.Bioequivalence study conducted in healthy volunteers comparing a formulation of alitretinoin with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, alitretinoin is a medicine that is used to treat severe chronic eczema that is unresponsive to treatment with potent topical corticosteroids.Skin - Dermatological conditionsACTRN12616001221448Zenith Technology Corp Ltd30
已完成
1 期
Comparative assessment of the absorption of a generic formulation of N-acetyl-5-methoxytryptamine prolonged release tablet against the innovator N-acetyl-5-methoxytryptamine prolonged release tablet conducted under fasting conditions in healthy male and female volunteers.-acetyl-5-methoxytryptamine is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.N-acetyl-5-methoxytryptamine is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.Mental Health - Other mental health disordersNeurological - Other neurological disordersACTRN12622000956707Zenith Technology Corporation Limited28